Danaher Co. (NYSE:DHR) Shares Sold by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC cut its stake in Danaher Co. (NYSE:DHR) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,412 shares of the conglomerate’s stock after selling 1,170 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Danaher were worth $17,101,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. acquired a new position in Danaher in the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of Danaher stock opened at $244.19 on Thursday. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average price is $234.84 and its two-hundred day moving average price is $253.53. The stock has a market cap of $176.38 billion, a PE ratio of 46.60, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

Several analysts have weighed in on DHR shares. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Barclays lowered their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.